Search Results for: knee replacement alternatives stem cell

Regenexx Des Moines | Iowa’s Regenexx Provider

Posted: October 15, 2017 at 9:16 am

Select a Problem Area

If you have pain, we're here to help. Regenexx Procedures are patented stem cell and blood platelet procedures that are used to treat a wide range of joint and spine conditions.

Click a problem area to discover what Regenexx can do for you.

The Regenexx family of non-surgical stem-cell & blood platelet procedures are next generation regenerative injection treatments for those who are suffering from shoulder pain due to arthritis, rotator cuff and shoulder labrum tears, overuse injuries, and other degenerative conditions. Regenexx is also a viable alternative for those considering shoulder replacement surgery.

View Details About Shoulder Treatments

Commonly Treated Conditions:

Shoulder Procedure Video

Regenexx Procedures are advanced stem cell and blood platelet procedures for foot and ankle conditions. Before you consider ankle surgery, fusion or replacement, consider the worlds leading stem cell and prp injection treatments.

View Details About Foot & Ankle Treatments

Commonly Treated Conditions:

Ankle Procedure Video

The Regenexx family of non-surgical stem-cell & blood platelet procedures are next generation regenerative injection treatments for those who are suffering from pain or reduced range of motion due to basal joint / cmc arthritis, hand arthritis, or other injuries & conditions in the hand.

View Details About Hand & Wrist Treatments

Commonly Treated Conditions:

The Regenexx family of non-surgical stem cell and blood platelet procedures offer next-generation injection treatments for those who are suffering from knee pain or may be facing knee surgery or knee replacement due to common injuries, arthritis, overuse and other conditions.

View Details About Knee Treatments

Commonly Treated Conditions:

ACL Procedure VideoIn-Depth with Dr. John Schultz ACL Procedure Video

The Regenexx family of non-surgical stem-cell & blood platelet procedures are next generation regenerative injection treatments for those who are suffering from pain, inflammation or reduced range of motion due tocommon elbow injuries, arthritis and overuse conditions.

View Details About Elbow Treatments

Commonly Treated Conditions:

The Regenexx family of hip surgery alternatives are breakthrough, non-surgical stem-cell treatments for people suffering from hip pain due to common injuries, hip arthritis & other degenerative problems related to the hip joint.

View Details About Hip Treatments

Commonly Treated Conditions:

Hip Labrum Procedure Video Hip Avascular Necrosis Procedure Video

Regenexx has many non-surgical platelet and stem cell based procedures developed to help patients avoid spine surgery and high dose epidural steroid side effects. These procedures utilize the patients own natural growth factors or stem cells to treat bulging or herniated discs, degenerative conditions in the spine, and other back and neck conditions that cause pain.

View Details About Spine Treatments

Commonly Treated Conditions:

Intradiscal Procedure Video

View Details About Spine Treatments

Commonly Treated Conditions:

Cervical Spine Video

See original here:
Regenexx Des Moines | Iowa's Regenexx Provider

Posted in Iowa Stem Cells | Comments Off

Regenexx Kansas City | Helping your body heal itself

Posted: September 24, 2017 at 6:59 am

Select a Problem Area

If you have pain, we're here to help. Regenexx Procedures are patented stem cell and blood platelet procedures that are used to treat a wide range of joint and spine conditions.

Click a problem area to discover what Regenexx can do for you.

View Details About Shoulder Treatments

Commonly Treated Conditions:

Shoulder Procedure Video

View Details About Foot & Ankle Treatments

Commonly Treated Conditions:

Ankle Procedure Video

View Details About Hand & Wrist Treatments

Commonly Treated Conditions:

View Details About Knee Treatments

Commonly Treated Conditions:

ACL Procedure VideoIn-Depth with Dr. John Schultz ACL Procedure Video

View Details About Elbow Treatments

Commonly Treated Conditions:

View Details About Hip Treatments

Commonly Treated Conditions:

Hip Labrum Procedure Video Hip Avascular Necrosis Procedure Video

View Details About Spine Treatments

Commonly Treated Conditions:

Intradiscal Procedure Video

View Details About Spine Treatments

Commonly Treated Conditions:

Cervical Spine Video

Posted in Kansas Stem Cells | Comments Off

Regenexx Las Vegas | Nevada’s Regenexx Provider

Posted: July 6, 2017 at 5:41 am

Select a Problem Area

If you have pain, we're here to help. Regenexx Procedures are patented stem cell and blood platelet procedures that are used to treat a wide range of joint and spine conditions.

Click a problem area to discover what Regenexx can do for you.

View Details About Shoulder Treatments

Commonly Treated Conditions:

View Details About Foot & Ankle Treatments

Commonly Treated Conditions:

View Details About Hand & Wrist Treatments

Commonly Treated Conditions:

View Details About Knee Treatments

Commonly Treated Conditions:

View Details About Elbow Treatments

Commonly Treated Conditions:

View Details About Hip Treatments

Commonly Treated Conditions:

View Details About Spine Treatments

Commonly Treated Conditions:

View Details About Spine Treatments

Commonly Treated Conditions:

Go here to read the rest:
Regenexx Las Vegas | Nevada's Regenexx Provider

Posted in Nevada Stem Cells | Comments Off

Overcoming Opioids: The quest for less addictive drugs – Colorado Springs Gazette

Posted: April 20, 2017 at 8:48 pm

Heidi Wyandt, 27, puts on her coat to leave the Altoona Center for Clinical Research in Altoona, Pa., on Wednesday, March 29, 2017, where she is helping test an experimental non-opioid pain medication for chronic back pain related to a work related injury she received in 2014. With about 2 million Americans hooked on opioid painkillers, researchers and drug companies are searching for less addictive drugs to treat pain. (AP Photo/Chris Post)

Tummy tucks really hurt. Doctors carve from hip to hip, slicing off skin, tightening muscles, tugging at innards. Patients often need strong painkillers for days or even weeks, but Mary Hernandez went home on just over-the-counter ibuprofen.

The reason may be the yellowish goo smeared on her 18-inch wound as she lay on the operating table. The Houston woman was helping test a novel medicine aimed at avoiding opioids, potent pain relievers fueling an epidemic of overuse and addiction.

Vicodin, OxyContin and similar drugs are widely used for bad backs, severe arthritis, damaged nerves and other woes. They work powerfully in brain areas that control pleasure and pain, but the body adapts to them quickly, so people need higher and higher doses to get relief.

This growing dependence on opioids has mushroomed into a national health crisis, ripping apart communities and straining police and health departments. Every day, an overdose of prescription opioids or heroin kills 91 people, and legions more are brought back from the brink of death. With some 2 million Americans hooked on these pills, evidence is growing that they're not as good a choice for treating chronic pain as once thought.

Drug companies are working on alternatives, but have had little success.

Twenty or so years ago, they invested heavily and "failed miserably," said Dr. Nora Volkow, director of the National Institute on Drug Abuse.

Pain is a pain to research. Some people bear more than others, and success can't be measured as objectively as it can be with medicines that shrink a tumor or clear an infection. Some new pain drugs that worked well were doomed by side effects Vioxx, for instance, helped arthritis but hurt hearts.

Some fresh approaches are giving hope:

"Bespoke" drugs, as Volkow calls them. These target specific pathways and types of pain rather than acting broadly in the brain. One is Enbrel, which treats a key feature of rheumatoid arthritis and, in the process, eases pain.

Drugs to prevent the need for opioids. One that Hernandez was helping test numbs a wound for a few days and curbs inflammation. If people don't have big pain after surgery, their nerves don't go on high alert and there's less chance of developing chronic pain that might require opioids.

Funky new sources for medicines. In testing: Drugs from silk, hot chili peppers and the venom of snakes, snails and other critters.

Novel uses for existing drugs. Some seizure and depression medicines, for example, can help some types of pain.

The biggest need, however, is for completely new medicines that can be used by lots of people for lots of problems. These also pose the most risk for companies and patients alike.

ONE DRUG'S BUMPY ROAD

In the early 2000s, a small biotech company had a big idea: blocking nerve growth factor, a protein made in response to pain. The company's drug, now called tanezumab (tah-NAZE-uh-mab), works on outlying nerves, helping to keep pain signals from muscles, skin and organs from reaching the spinal cord and brain good for treating arthritis and bad backs.

Pfizer Inc. bought the firm in 2006 and expanded testing. But in 2010, some people on tanezumab and similar drugs being tested by rivals needed joint replacements. Besides dulling pain, nerve growth factor may affect joint repair and regeneration, so a possible safety issue needed full investigation in a medicine that would be the first of its type ever sold, said one independent expert, Dr. Jianguo Cheng, a Cleveland Clinic pain specialist and science chief for the American Academy of Pain Medicine.

Regulators put some of the studies on hold. Suddenly, some people who had been doing well on tanezumab lost access to it. Phyllis Leis in Waterfall, a small town in south-central Pennsylvania, was one.

"I was so angry," she said. "That was like a miracle drug. It really was. Unless you have arthritis in your knees and have trouble walking, you'll never understand how much relief and what a godsend it was."

Her doctor, Alan Kivitz of Altoona Center for Clinical Research, has helped run hundreds of pain studies and consults for Pfizer and many other companies. "You rarely get people to feel that good" as many of them did on the nerve growth factor drugs, he said.

A drug with that much early promise is unusual, said Ken Verburg, who has led Pfizer's pain research for several decades.

"When you do see one, you fight hard to try to bring one to the market," he said.

An independent review ultimately tied just a few serious joint problems to tanezumab and the suspension on testing was lifted in August 2012. But a new issue nervous system effects in some animal studies prompted a second hold later that year, and that wasn't lifted until 2015.

Now Eli Lilly & Co. has joined Pfizer in testing tanezumab in late-stage studies with 7,000 patients. Results are expected late next year about 17 years after the drug's conception.

AVOIDING PAIN TO AVOID DRUGS

What if a drug could keep people from needing long-term pain relief in the first place? Heron Therapeutics Inc. is testing a novel, long-acting version of two drugs the anesthetic bupivacaine and the anti-inflammatory meloxicam for notoriously painful operations like tummy tucks, bunion removal and hernia repair.

Company studies suggest it can numb wounds for about three days and cut patients' need for opioids by 30 to 50 percent.

There's a good chance of preventing brain responses that lead to chronic pain if patients can get through that "initially very rough period," said Dr. Harold Minkowitz, a Houston anesthesiologist who consults for Heron and treated Hernandez in the tummy tuck study.

Hernandez was part of an experiment testing the drug versus a placebo and doesn't know whether she got the drug or a dummy medicine. But she hurt less than she expected to and never filled a prescription for pain pills.

"The goal would be to have half or more of patients not requiring an opiate after they go home," said Heron's chief executive, Barry Quart. "You have far fewer opiates going out into society, far fewer opiates sitting in medicine cabinets that make their way to a high school."

Studies so far are mid-stage too small to prove safety and effectiveness but Heron plans more aimed at winning approval.

ON THE HORIZON

Many companies have their eyes on sodium channel blockers, which affect how nerves talk to each other and thus might help various types of pain. Others are testing cell therapies for nerve pain. Stem cells can modulate immune responses and inflammation, and may "overcome a raft of problems," said Cheng of the pain medicine academy.

Some companies, including Samumed, Centrexion Therapeutics and Flexion Therapeutics, are testing long-acting medicines to inject in knees to relieve arthritis pain. Samumed's aims to regenerate cartilage.

And then there's marijuana. A cannabis extract is sold as a mouth spray in Britain for nerve pain and other problems from multiple sclerosis. But cannabinoid research in the U.S. has been hampered by marijuana's legal status. A special license is needed and most researchers don't even try to obtain one, said Susan Ingram, a neurosurgery scientist at Oregon Health & Science University.

She is studying cannabinoid receptors in the brain, looking at how pain affects one type but not another. Such work might someday lead to drugs that relieve pain but don't produce a high or addiction.

Selective activity has precedent: The drug buprenorphine partially binds to opioid receptors in the brain and has become "an extraordinarily successful medication" for treating addiction, said Volkow, of the national drug institute.

"It has shown pharmaceutical companies that if you come up with a good intervention, there is an opportunity to recover their costs," she said.

___

Marilynn Marchione can be followed at http://twitter.com/MMarchioneAP

See original here:
Overcoming Opioids: The quest for less addictive drugs - Colorado Springs Gazette

Posted in Colorado Stem Cells | Comments Off

How new-age medicine is helping Major League Baseball pitchers avoid injury – Pittsburgh Post-Gazette

Posted: March 31, 2017 at 3:48 am

BRADENTON, Fla. By now, the time line for recovery from Tommy John surgery is familiar even to the casual baseball fan. It takes at least a year, usually more. It takes tedious, monotonous work on the part of the player.

Alternatives exist, but until now their use among established major leaguers has been limited if tried at all. This season could provide a referendum on two of them. One surgical procedure could cut the recovery time in half. Another treatment could help a player avoid surgery altogether.

I think it can definitely help the game, right-hander Seth Maness, who had a modified elbow ligament surgery in August, said by phone from spring training in Arizona. But the circumstances have to be right.

Maness had a surgery on his right elbow known as a primary repair or primary brace. The procedure reattaches the elbows ulnar collateral ligament to the bone with collagen-coated Arthrex tape. Los Angeles Angels starter Garrett Richards received a stem cell injection into his right elbow to heal his damaged UCL. So far, its working.

The last thing you want to do is have surgery, and if you do what your body does naturally, thats going to be stronger than any replacement surgery, Richards said, also by phone from spring training in Arizona. I just hope that this further gives guys a little bit of knowledge that you have options.

Neither procedure will replace Tommy John. Stem cells dont work in every case, and if the UCL is torn across the middle of the ligament, it needs to be replaced. The sample size for both is also small. But both provide options involving less recovery time for pitchers whose injuries fit a certain profile.

Maness, 28, spent four seasons pitching out of the St. Louis Cardinals bullpen and signed a minor league contract with the Kansas City Royals in February. Maness ligament had pulled away from the bone rather than tearing across the middle. Instead of needing a full Tommy John surgery, which requires grafting a tendon from the wrist or hamstring into the elbow to replace the UCL and at least a year of recovery, Maness was a candidate for a primary repair.

Really this primary brace technology had been used more widely in Europe, particularly for ligament injuries of the knee and the ankle, said Dr. George Paletta, St. Louis Cardinals head orthopedic surgeon who performed Maness surgery. So the concept or the idea was, OK, its working well there, is there a way to adapt it to the elbow?

Paletta had done roughly 60 primary repairs on amateur pitchers prior to operating on Maness and saw an average recovery time of 6 months. That background helped him establish three criteria he needed a young pitcher, an otherwise healthy ligament and, most importantly,the ligament needed to pull off the bone on one end rather than tear in the middle.

Weve had a lot of experience with ligaments healing directly to bone and we have a good understanding of that timetable, so we knew that by about 12 weeks after surgery, this repair should be pretty well healed and pretty solid at that point, Paletta said.

Cardinals reliever Mitch Harris also had the primary repair, as did a third pitcher with major league experience, according to the St. Louis Post-Dispatch, with whom Maness first discussed the procedure in January. Cardinals non-roster outfielder/pitcher Jordan Schafer had the procedure this month.

The UCL in Richards right elbow had a tear running along the ligament, not across it. He sought second opinions from noted orthopedic surgeons Dr. James Andrews and Dr. Neal ElAttrache.

Dr. Andrews pretty much told me, Hey Garrett, if you were my son, I would try the stem cell first, Richards said.

Doctors removed stem cells from his pelvis and injected them into his elbow, in hopes the cells would heal the UCL. Stem cells, extracted from bone marrow, are able to develop into multiple different tissues and can promote healing.

It just feels tight. Youre putting fluid into a place that pretty much doesnt have any room for any more fluid, Richards said of the injection. If you can imagine youre just overfilling a certain area with this nice special sauce.

Teams sometimes use platelet-rich plasma injections, where blood is spun in a centrifuge to isolate growth factors Takashi Saitos PRP injection in 2008 was believed to be the first for a major league pitcher, and Masahiro Tanaka also has pitched successfully with a partially torn UCL after PRP treatment but stem cells are less common. Bartolo Colon, soldiering into his 20th major league season at 43 years old, had a stem cell treatment in 2010. Boston Red Sox left-hander Drew Pomeranz had a stem cell injection in his elbow this winter to address lingering soreness.But Pomeranz went on the disabled list Thursday with left forearm flexor strain.

It doesnt always work. Richards teammate, lefty Andrew Heaney, needed Tommy John last summer after stem cells didnt do the trick.

Richards six-week exam showed significant growth. His three-month check showed even more. He reported no issues this spring, his high-90s mph fastball is back and he is on track to open the season in the rotation.

Everything feels great, Richards said. Basically I took the year off, let my arm heal and now Im back doing what I always do. I just feel refreshed.

Bill Brink: bbrink@post-gazette.com and Twitter @BrinkPG.

Read the original post:
How new-age medicine is helping Major League Baseball pitchers avoid injury - Pittsburgh Post-Gazette

Posted in Cell Medicine | Comments Off

Sarasota Orthopedic Surgeon Dr. William Bennett Launches New Website

Posted: November 24, 2014 at 5:52 am

Sarasota, FL (PRWEB) November 24, 2014

Dr. William Bennett, one of the top orthopedic surgeons in Florida and owner of Bennett Orthopedics and Sportsmedicine, recently announced the launch of his practices completely redesigned website. The website, which can be found at BennettOrthoSportsMed.com, helps clients connect to the talented doctors PRP, stem cells, arthritis, and pain and injury services.

When treating his patients, Dr. Bennett uses a variety of techniques; he is trained in a variety of procedures, such as nonsurgical and surgical treatment, physical therapy, and stem cell therapy. He is highly regarded in his field, especially because he provides alternatives to surgery when needed. Dr. Bennett has five years of experience and combines it with a minimally invasive approach, ensuring that clients always receive the most attentive, specialized, and comfortable care possible.

According to the website, Dr. Bennetts career has spanned almost 15 years. At present, he is the only doctor serving patients in Tampa to Port Charlotte with custom knee replacements and minimally invasive surgeries. Dr. Bennett is also the only practitioner performing platelet rich plasma (PRP) therapy on clients with orthopedic needs.

With Dr. Bennetts technique, most patients can walk without a cane in two weeks, and some patients can even begin walking within two days.

Some of my former patients remarked that it feels like their normal knee, stated Dr. Bennett. Additionally, I, the surgeon, can not tell the difference between this custom knee and a normal knee when I perform my examinations.

Individuals interested in learning more about Dr. Bennett and PRP therapy in Sarasota can visit the orthopedic surgeons website for additional information. Clients can also subscribe to Dr. Bennetts Facebook, Twitter, YouTube, and LinkedIn accounts for frequent updates about the doctors practice.

About Dr. William Bennett:

Designated one of the Top Orthopedic Surgeons in Sarasota by U.S. News and World Reports, Dr. Bennett has been practicing since 1995. He is a highly skilled, experienced orthopedic surgeon with dual fellowships in Sports medicine-arthroscopy and shoulder surgery. Sarasota Magazine and Castle Connolly Medical ranked him a Top Doctor for Orthopedic Surgery for 2013. For more information, please visit http://www.bennettorthosportsmed.com

See the article here:
Sarasota Orthopedic Surgeon Dr. William Bennett Launches New Website

Posted in Florida Stem Cells | Comments Off

More Local News

Posted: January 20, 2014 at 10:44 pm

(WFLA) When Judy Loar, 68, could not bear to walk any longer due to excruciating pain in both of her knees from degenerative joint disease, she did what most people in her condition do, she went in for a surgical knee replacement.

After being released, Loar found out her knee cap had been set incorrectly.

Going through surgery again to fix her other knee was not an option, so Loar started researching other alternatives to ease the agony of bone-on-bone friction caused by her condition.

"I really did my research, because I knew I could go through another major surgery," said Loar who became a patient of Dr. Dennis Lox.

Dr. Lox is the founder and medical director of Tampa-based Florida Spine and Sports Medicine Center, and one of the world's leading doctors specializing in using stem cell therapy as an alternative to successfully treat debilitating injuries or conditions.

Loar describes the procedure as painless, with no down time.

Histogenics Honored as a 2012 “Fierce 15” Company by FierceMedicalDevices

Posted: October 2, 2012 at 8:14 pm

WALTHAM, Mass.--(BUSINESS WIRE)--

Histogenics, a regenerative medicine company combining cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration, announced today that it has been named to the FierceMedicalDevices Fierce 15 list, designating it as one of the leading medical device and diagnostic companies of 2012. FierceMedicalDevicesEditors Mark Hollmer and Damian Garde, in conjunction with Editor-in-Chief John Carroll and Executive Editor Ryan McBride, chose this years winners based on their top management teams, notable financial backing, and promising technologies and market opportunities.

We have worked hard over the past year, securing $49 million in financing and adding key new staff, investors and board members, so that we are now in the position to focus our full attention on continued successful clinical and regulatory execution for NeoCart cartilage regeneration implant, which is currently enrolling patients into the Phase 3 IND clinical study, and the EU regulatory development of our VeriCart cartilage repair scaffold, said Patrick ODonnell, President and Chief Executive Officer of Histogenics. We believe our product candidates have the potential to transform the treatment of cartilage injury with the goal of returning some of the estimated 1.8 million patients each year in the U.S. and E.U. that undergo arthroscopy for knee cartilage defects to their pre-injury level of activity.

Nailing down $49 million in financing in July reinforces the notion that this regenerative medicine company stands out for doing things differently.One example how: The company is well underway enrolling patients in a Phase 3 trial for NeoCart, a cartilage implant that uses a patients own cells to build it before treating cartilage lesions in the knee, said Hollmer.

NeoCart is an autologous neocartilage tissue implant in an ongoing Phase 3 clinical program that utilizes the patients own cells to regenerate cartilage in patients suffering from cartilage lesions in the knee.VeriCart, is a single-step, cell-free collagen scaffold uniquely designed to be used in conjunction with the patients own stem cells to repair small cartilage defects frequently observed in meniscal and anterior cruciate ligament repair procedures. Histogenics is seeking regulatory clearance in the European Union for VeriCart.

An internationally recognized e-newsletter reaching more than 34,000 medical device and diagnostic industry professionals, FierceMedicalDevices provides subscribers with a quick authoritative briefing on the days top stories, with a special focus on clinical studies, FDA/EMEA regulations and post-marketing. Sign up is free at http://www.fiercemedicaldevices.com/signup.

About FierceMarkets

FierceMarkets, a wholly owned subsidiary of Questex Media Group, is a leader in B2B emedia, providing information and marketing services in the telecommunications, life sciences, healthcare, IT, energy, government and finance industries through its portfolio of email newsletters, websites, webinars and live events. Every business day, FierceMarkets wide array of publications reaches more than 1.3 million executives in more than 100 countries.

About Histogenics

Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. In May of 2011, Histogenics acquired Israeli cell-therapy company ProChon BioTech. Histogenics flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials in which the NeoCart autologous tissue implants effectiveness is compared to that of standard microfracture surgery. Based in Waltham, Massachusetts, the company is privately held. For more information, visitwww.histogenics.com.

Read this article:
Histogenics Honored as a 2012 “Fierce 15” Company by FierceMedicalDevices

Posted in Cell Therapy | Comments Off

Histogenics Honored as a 2012 “Fierce 15” Company by FierceMedicalDevices

Posted: October 2, 2012 at 7:21 pm

WALTHAM, Mass.--(BUSINESS WIRE)--

About FierceMarkets

About Histogenics

Read the original:
Histogenics Honored as a 2012 “Fierce 15” Company by FierceMedicalDevices

Posted in Cell Therapy | Comments Off

Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage …

Posted: July 24, 2012 at 12:12 pm

WALTHAM, Mass.--(BUSINESS WIRE)--

Regenerative medicine company Histogenics Corporation, announced today the completion of a $49 million round of financing. The syndicate was led by Sofinnova Ventures with participation from additional new investors Split Rock Partners, BioMed Ventures and FinTech GIMV Fund, L.P. Existing investors ProChon Holdings BV, Altima Partners, Foundation Medical Partners, Inflection Point Capital and Boston Millennia Partners also participated in the financing. Proceeds will be used to complete the ongoing Phase 3 clinical program for lead product candidate NeoCart, which is currently enrolling patients. NeoCart is an autologous neocartilage tissue implant that utilizes the patients own cells to regenerate cartilage in patients suffering from cartilage lesions in the knee. Funds will also support efforts to obtain regulatory clearance in the European Union for product candidate VeriCart, a single-step, cell-free collagen scaffold uniquely designed to be used in conjunction with the patients own stem cells, to repair small cartilage defects frequently observed in meniscal and anterior cruciate ligament repair procedures. Garheng Kong, MD, PhD of Sofinnova Ventures and Josh Baltzell of Split Rock Venture Partners will join Histogenics Board of Directors. Arnold Freedman of Boston Equity Advisors served as the exclusive placement agent.

Patrick ODonnell, President and Chief Executive Officer of Histogenics, commented, We believe the quality of the investors and the significant level of commitment demonstrated in this financing speak to the potential of our product candidates to transform the treatment of cartilage injury with the goal of returning patients to their pre-injury level of activity. Each year, 1.8 million active adults and elite athletes undergo arthroscopy for the diagnosis and treatment of painful cartilage defects in the knee. With continued positive clinical results, we believe our Phase 3 product candidate, NeoCart, has considerable potential as a much-needed treatment alternative for a significant portion of these patients. The successful completion of this financing fully funds the Company to reach key clinical and commercial milestones for NeoCart and VeriCart and allows us to focus our full attention on continued successful clinical and regulatory execution.

Garheng Kong, MD, PhD, General Partner of Sofinnova Ventures added, NeoCart has the potential to dramatically change the way knee cartilage injuries are treated. Current treatments for knee cartilage damage frequently do not produce the lasting effects that individuals need to avoid serious knee pain and improve functionpreventing them from getting back to their active, daily lives. Published data have shown that patients treated with NeoCart experienced a very durable response that is sustained throughout a period of four years or more. Sofinnova is pleased to support Histogenics efforts to receive approval for NeoCart and address this unmet clinical need.

About NeoCart NeoCartis an autologous bioengineered neocartilage grown outside the body using the patients own cells for the regeneration of cartilage lesions. NeoCart recently entered a Phase 3 clinical trial after reporting positive Phase 2 data, in which all primary endpoints were met, and NeoCart was found to be generally well tolerated.

About VeriCart VeriCart is a single step, off-the-shelf, cell-free collagen scaffold, specifically designed for cartilage applications, which when reconstituted with the patients own bone marrow or augmenting marrow stimulation procedures, is intended for the improved repair of cartilage tissue. VeriCart is currently in development.

About Histogenics Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. In May of 2011, Histogenics acquired Israeli cell-therapy company ProChon BioTech. Histogenics flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials in which the NeoCart autologous tissue implants effectiveness is compared to that of standard microfracture surgery. Based in Waltham, Massachusetts, the company is privately held. For more information, visitwww.histogenics.com.

About Sofinnova Ventures Sofinnova Ventures has over 40 years of experience building start-ups and later stage companies into market leaders. With $1.4 billion under management, the firm applies capital and expertise to build companies from inception to exit. Sofinnova closed its life science-focused $440M, SVP VIII, in late 2011. The firms investment team of MDs and PhDs has significant scientific, operational and strategic experience, and specializes in financing later stage clinical products. The Sofinnova team partners with entrepreneurs to address patients unmet medical needsand has had a string of recent exits through companies, including Movetis, Preglem, Amarin, Vicept and Intellikine.

About Split Rock Partners Split Rock Partners, with offices in Minneapolis and Menlo Park, seeks emerging opportunities in healthcare as well as software and internet services. Since 2005, Split Rock has raised $575 million over two funds. Representative companies backed by Split Rock's team include Ardian, Atritech, DFine, Entellus, eBureau, Evalve, Guardian Analytics, HireRight, Intacct, LowerMyBills, MyNewPlace, QuinStreet (QNST), SPS Commerce (SPSC) and Tornier (TRNX). Additional information about the firm can be found atwww.splitrock.com.

See the rest here:
Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage ...

Posted in Regenerative Medicine | Comments Off

Search Results for: knee replacement alternatives stem cell

Regenexx Des Moines | Iowa’s Regenexx Provider

Regenexx Kansas City | Helping your body heal itself

Regenexx Las Vegas | Nevada’s Regenexx Provider

Overcoming Opioids: The quest for less addictive drugs – Colorado Springs Gazette

How new-age medicine is helping Major League Baseball pitchers avoid injury – Pittsburgh Post-Gazette

Sarasota Orthopedic Surgeon Dr. William Bennett Launches New Website

More Local News

Histogenics Honored as a 2012 “Fierce 15” Company by FierceMedicalDevices

Histogenics Honored as a 2012 “Fierce 15” Company by FierceMedicalDevices

Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage …

Categories

Archives

Recommended Sites

Contact Us

Recent Posts